Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950925 | 1.00 | MGLL (0.39) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL3783762 | 0.89 | MGLL (0.43) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL146988 | 0.81 | CES2 (0.42) | MGLLCES2CES1 | |
| SCHEMBL24425169 | 0.81 | CA2 (0.46) | MGLLALDH1A1POLBTDP1CA2 | |
| SCHEMBL1396708 | 0.81 | MGLL (0.38) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL23273035 | 0.81 | MGLL (0.38) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL29951922 | 0.81 | MGLL (0.38) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL24425048 | 0.79 | CA2 (0.45) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL13125382 | 0.79 | TYK2 (0.39) | MGLLALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL29956479 | 0.79 | GABRA1 (0.39) | MGLLALDH1A1POLBTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| CN-118302418-B | Aromatic heterocyclic compound and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| US-20250042862-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4431504-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2024-09-18 | — | — | EP | disclosed |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| CN-118302418-A | Aromatic heterocyclic compound and application thereof | 中国科学院上海药物研究所 | 2024-07-05 | — | — | CN | disclosed |
| CN-113767106-B | Oxazaquinazolin-7 (8H) -ones, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-02-13 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | MGLL 4273/4885ALDH1A1 2205/4885POLB 1412/4885 |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MGLL 2486/4885ALDH1A1 4010/4885POLB 4723/4885 |
| US-11897891-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | MGLL 2704/4885ALDH1A1 879/4885POLB 1747/4885 |
| US-20250042862-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | KDM1B, KDM1A, KDM3B | MGLL 2643/4885ALDH1A1 165/4885POLB 2384/4885 |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | MGLL 2704/4885ALDH1A1 879/4885POLB 1747/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | MGLL 2420/4885ALDH1A1 478/4885POLB 2353/4885 |
| US-20140088117-A1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | MGLL 4614/4885ALDH1A1 3026/4885POLB 3142/4885 |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | MGLL 2475/4885ALDH1A1 1253/4885POLB 4330/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | MGLL 4273/4885ALDH1A1 2205/4885POLB 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.